A new study in Current Medicinal Chemistry C. Belli and colleagues published analysis of angiogenic factors in cancer development of malignant mesothelioma.
Angiogenesis is the process of growth of new blood vessels from existing vessels. Researchers believe that a better understanding of the molecular mechanisms and pathways involved in angiogenesis, the basis for the development of new drugs against malignant mesothelioma. These drugs against these pathways may affect the proliferation and survival of tumor cells.
The standard treatment for patients with mesothelioma is chemotherapy with cisplatin and pemetrexed combination of drugs. However, the use of chemotherapy did not always have a significant impact on improving survival rate. The average life expectancy of mesothelioma varies between four and 18 months after diagnosis.
Mesothelioma is a cancer caused almost exclusively by asbestos. The main reason why most patients are diagnosed at an advanced stage of development is that the latency of severe symptoms. The symptoms often occur once the cancer has already developed, sometimes up to 50 years from the time that someone has been exposed to asbestos first.
The study examined the role of angiogenic factors in tumor development by reviewing the results of clinical studies, articles, abstracts and presentations of the American Society of Clinical Oncology. Information on clinical trials in ClinicalTrials.gov found.
According to the researchers activated the hope of a better understanding of the process of angiogenesis in malignant mesothelioma, to provide new therapeutic options for these patients in the future.
Make you know about mesothelioma lawyers,asbestos lawyers and mesothelioma treatments knowledge
